KNC Laboratories

Basic Information

Stock Code
6568
Industry
Services
Category Detail
Chemicals & Chemical Products
Prefecture
Hyogo Prefecture
Establishment Year
January 1985
Listing Year
March 2018
Official Website
https://www.kncweb.co.jp/
TSE Information
TSE Information
Yahoo! Finance
Yahoo! Finance
Other Companies
Osaka Organic Chemical Industry, KH Neochem, Manac CP, WDB Coco, Matsuya R&D

Overview

KNC Laboratories is a pioneering company in contract research and development services founded in 1985, with strengths in organic synthetic chemistry and biotechnology, providing advanced support to diverse industries.

Current Situation

KNC Laboratories recorded net sales of approximately 2.6 billion yen and operating profit of approximately 200 million yen for the fiscal year ended March 2021, maintaining a stable financial foundation. Its core business is contract R&D services utilizing organic synthetic chemistry and biochemistry technologies, earning trust from a wide range of pharmaceutical and chemical companies. It operates multiple research institutes and factories domestically, focusing on quality management and technology development. In recent years, it has pursued large-scale investments in culture facilities and other equipment to enhance manufacturing capabilities. In terms of sustainability, it is engaged in technology development aimed at reducing environmental impact. After listing on the Tokyo Stock Exchange Growth Market, it has leveraged raised funds to expand business scale and strengthen R&D capabilities. In the future, it aims to focus on the biotechnology sector and global expansion. Moving forward, it will continue to leverage advanced specialized technologies to provide ongoing development support tailored to customer needs.

Trivia

Interesting Facts

  • High track record in domestic contract research since founding in 1985
  • Listed on Tokyo Stock Exchange Growth Market in 2018
  • One of Japan's first contract R&D service companies
  • Operates three research and manufacturing sites domestically
  • Possesses proprietary synthesis technologies with patents
  • Particularly strong in culture facilities for bio field
  • Approximately 300 technical staff
  • Rich track record of contracts from diverse industries
  • Founder is an expert in organic chemistry
  • Adopts quality management system based on international standards
  • Capable of custom synthesis tailored to customer needs
  • Flexible small-lot, multi-variety production
  • Integrated support for raw material procurement and manufacturing
  • Research institutes located in Kobe and Izumo
  • Actively engages in community contribution activities

Hidden Connections

  • Built deep long-term partnerships with multiple major domestic pharmaceutical companies
  • Participating in regional bio industry revitalization projects in collaboration with Kobe City
  • Conducts numerous joint research projects with university institutions to enhance technologies
  • Has influence in the Chinese market through affiliates and joint ventures
  • Actively participates in technical committees of industry associations
  • Among domestic bio contract companies, has high level of culture facility completeness
  • Has been adapting to diverse chemical fields since founding
  • Quality assurance department contributed to ISO certification acquisition and standardization

Future Outlook

Growth Drivers

  • Expansion of bio-pharmaceutical market
  • Increasing sophistication of contract R&D needs
  • Rising pharmaceutical development investments domestically and internationally
  • Growing demand for environmentally responsive manufacturing technologies
  • New applications development through culture technology innovations
  • Business efficiency improvements via IoT and AI adoption
  • Expansion of global partnerships
  • Growth in demand for sustainable chemicals
  • Diversification of custom synthesis services
  • Increasing demand for development support from small and medium pharmaceutical companies
  • Strengthening regional medical and industrial collaborations
  • Ongoing increase in R&D investments

Strategic Goals

  • Achieve net sales exceeding 5 billion yen
  • Expand market share in biotechnology field
  • Optimize contract production system using culture facilities
  • Establish zero-environmental-impact manufacturing processes
  • Strengthen partnerships with major domestic and international pharmaceutical companies
  • Promote digital transformation
  • Establish ongoing training system to enhance employee expertise
  • Achieve top ESG evaluation ranking
  • Accelerate development of new technologies and services
  • Incorporate and promote community contributions into management strategy

Business Segments

Pharmaceutical Manufacturing Support

Overview
Provides various contract services from R&D to manufacturing for pharmaceuticals.
Competitiveness
Product development support through integrated organic and bio technologies
Customers
  • Pharmaceutical Companies
  • Bio Ventures
  • Pharmaceutical Raw Material Manufacturers
  • University Labs
  • Medical Device Manufacturers
Products
  • Pharmaceutical APIs and Intermediates
  • Manufacturing Process Development
  • Quality Analysis Services
  • Stable Isotope Compounds
  • Culture Facility Utilization

Chemical Contract Manufacturing

Overview
Focuses on contract synthesis and manufacturing services for chemical products across a wide range of industries.
Competitiveness
High precision in synthesis and quality control technologies
Customers
  • Chemical Manufacturers
  • Electronic Materials Manufacturers
  • Functional Materials Manufacturers
  • Agrochemical Manufacturers
  • Materials Research Institutes
Products
  • Organic Chemicals Synthesis
  • High-Purity Intermediates
  • Functional Materials Raw Materials
  • Manufacturing Consulting
  • Custom Synthesis

Biotechnology Development Support

Overview
R&D and manufacturing support services leveraging cutting-edge bio technologies.
Competitiveness
Accumulated expertise in diverse culture and testing technologies
Customers
  • Biotechnology Companies
  • Pharmaceutical Development Organizations
  • University Researchers
  • Public Research Institutions
Products
  • Cell Culture Technology
  • Protein Synthesis Contract
  • Bioreactor Development
  • Gene-Related Testing

R&D Consulting

Overview
Provides technology consulting at the R&D stage to support efficient development.
Competitiveness
Extensive R&D know-how and networks
Customers
  • Pharmaceutical Companies
  • Chemical Manufacturers
  • New Business Development Departments
Products
  • Technology Evaluation
  • Synthesis Design Support
  • Market Research
  • Quality Assurance Support

Equipment Investment and Technology Introduction Support

Overview
Supports enhancement of customer technical capabilities through installation of culture facilities and technology transfer.
Competitiveness
On-site responsiveness and equipment expertise
Customers
  • Small and Medium Enterprises
  • Research Institutions
  • Startups
Products
  • Culture Facility Installation
  • Technology Transfer Support
  • Training

Competitive Advantage

Strengths

  • Advanced organic synthesis technology
  • Biochemistry expertise
  • Enhanced manufacturing capacity through multi-site operations
  • Stable financial base
  • Long track record in research contracts
  • Technical research institute and lab network
  • Flexible response to customer needs
  • High-quality management system
  • Mass production support with latest equipment
  • Experienced technical staff
  • Trusted relationships with domestic and international pharmaceutical manufacturers
  • Active equipment investments
  • Reliability as a Tokyo Stock Exchange Growth Market-listed company
  • Expansion into diverse industry sectors
  • Integrated support from R&D to manufacturing

Competitive Advantages

  • Strength in integration of organic synthesis and bio technology
  • Capability to handle a wide range of manufacturing processes on contract
  • Accumulated know-how from long-term contract research
  • Superior capability in small-lot, multi-variety production
  • Integrated service system from research to mass production
  • Differentiation through specialized culture facilities
  • Strong partnerships with major domestic pharmaceutical companies
  • High technical consulting capabilities
  • Flexibility and rapid response to new technology introductions
  • Thorough quality and delivery management
  • Regionally integrated production system
  • Continuous investment in cutting-edge technologies
  • Development of low-environmental-impact technologies
  • Transparency in equipment investment plans
  • Enhanced employee expertise and training programs

Threats

  • Increasing domestic and international competitors
  • Risk of raw material price fluctuations
  • Rising costs for stricter environmental regulations
  • Risk of reduced R&D projects
  • Rapid obsolescence of technologies
  • Intensifying price competition in global markets
  • Trend toward in-house production by customers
  • Challenges in securing talent due to labor shortages
  • Profit volatility from exchange rate fluctuations
  • Production facility risks from natural disasters
  • IP infringement risks
  • Social uncertainties such as pandemic outbreaks

Innovations

2023: New Advanced Culture Facilities

Overview
New large-scale culture facilities installed to strengthen production capacity and quality control.
Impact
Improved production efficiency and contract project acquisition capabilities

2022: Introduction of Automation in Organic Synthesis Processes

Overview
Introduced automation systems for precision organic synthesis to improve production efficiency.
Impact
Contributes to reduced work time and stabilized quality

2021: Launch of Biotechnology Development Program

Overview
Strengthened research on cell culture technology and initiated commercialization studies.
Impact
Established foundation for new bio product development

2024: Adoption of Environmentally Considerate Manufacturing Technologies

Overview
Introduced manufacturing methods aimed at energy savings and waste reduction.
Impact
Significant reduction in environmental impact

2020: Advanced Quality Management System

Overview
Introduced latest analytical equipment to strengthen quality assurance system.
Impact
Contributes to improved product reliability

Sustainability

  • Establishment of low-environmental-impact manufacturing processes
  • Promotion of waste reduction and recycling
  • Introduction of energy-saving equipment
  • Promotion of participation in local environmental protection activities
  • Employee environmental awareness training
  • Development of sustainable chemical synthesis technologies
  • Strengthened safety and health management system
  • Promotion of green procurement policies
  • Active utilization of ESG evaluations
  • Promotion of social contribution activities